{"id":11960,"date":"2026-07-25T14:30:00","date_gmt":"2026-07-25T06:30:00","guid":{"rendered":"https:\/\/credevo.com\/articles\/?p=11960"},"modified":"2026-07-25T18:14:48","modified_gmt":"2026-07-25T10:14:48","slug":"vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed","status":"publish","type":"post","link":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/","title":{"rendered":"Vietnam for Clinical Trials in 2026: Regulatory Landscape, Site Quality, and What Has Changed"},"content":{"rendered":"\n<p>Vietnam has been on the periphery of APAC clinical trial planning for most of the last decade, considered after Thailand, Malaysia, and India if considered at all. That positioning is no longer accurate. Since 2022, the Drug Administration of Vietnam (DAV) has shortened approval timelines, the ethics committee landscape has become more predictable, and investigator depth in oncology and infectious disease has grown meaningfully. Sponsors who last assessed Vietnam three years ago are working from an outdated picture.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-1024x576.png\" alt=\"Vietnam for Clinical Trials in 2026\" class=\"wp-image-11963\" srcset=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-1024x576.png 1024w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-300x169.png 300w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-768x432.png 768w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-1536x864.png 1536w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-732x412.png 732w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-1140x641.png 1140w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo.png 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>This article covers where Vietnam stands as a trial destination in 2026: what the regulatory pathway looks like today, where site and investigator quality is strongest, what has genuinely improved, and what limitations still apply.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote has-blush-light-purple-gradient-background has-background is-layout-flow wp-block-quote-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Key takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-small-font-size\">DAV has aligned more closely with ICH guidelines since 2022, and Phase II approval timelines have shortened from a typical 9 to 12 months to 6 to 9 months in most therapeutic areas.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Vietnam&#8217;s investigator depth is strongest in oncology (particularly lung, gastric, and colorectal cancer) and infectious disease, driven by its high-volume tertiary hospital network.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Ethics committee approval, historically the longest and least predictable step, has become more consistent following Ministry of Health consolidation of independent ethics committees.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Vietnam&#8217;s patient population offers genuine treatment-naive advantage in oncology and infectious disease, with lower competing-trial density than Thailand or India.<\/li>\n\n\n\n<li class=\"has-small-font-size\">IMP import remains complex. A dedicated Importer of Record (IOR) service is strongly recommended for sponsors without prior in-country operations.<\/li>\n\n\n\n<li class=\"has-small-font-size\">For sponsors already running trials in Thailand or Malaysia, Vietnam adds meaningful portfolio diversification and patient access without requiring a fundamentally different operational model.<\/li>\n<\/ul>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-05687eb1dab7349eb549c094ec34e5f1\">Vietnam&#8217;s regulatory pathway for clinical trials in 2026<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Regulatory authority in Vietnam<\/h4>\n\n\n\n<p>Clinical trials in Vietnam are regulated by the Drug Administration of Vietnam (DAV), operating under the Ministry of Health. All Phase I\u2013IV interventional trials require approval from both the DAV and an Ethics Committee before site activation.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Recent changes<\/h4>\n\n\n\n<p>The most significant procedural change of the last two years is that the approval sequence now runs in parallel rather than in series since 2023. DAV technical review and EC review can proceed simultaneously, where previously sponsors waited for DAV clearance before submitting to the EC. In practice, this has removed four to six weeks from the average startup timeline.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">DAV&#8217;s GCP framework<\/h4>\n\n\n\n<p>DAV&#8217;s GCP framework was formally aligned with ICH E6(R2) in 2021, with further guidance issued in 2024 that incorporates elements of <a href=\"https:\/\/www.ich.org\/page\/efficacy-guidelines\">ICH E6(R3)<\/a>. This alignment matters for multinational trial submissions: the same data package that satisfies FDA or EMA requirements is largely accepted by DAV without additional reformatting.<\/p>\n\n\n\n<p>Current indicative timelines for Phase II approval in Vietnam:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>DAV technical review: 3 to 5 months<\/li>\n\n\n\n<li>Ethics committee review: 2 to 4 months (running in parallel with DAV review)<\/li>\n\n\n\n<li>Total from complete submission to first approval: 4 to 6 months in straightforward cases; 6 to 9 months for complex protocols<\/li>\n<\/ul>\n\n\n\n<p>These timelines are meaningfully shorter than three years ago, though still longer than Singapore (3 to 4 months) or Australia&#8217;s CTA pathway. Sponsors planning Vietnam as the sole study country should build in a 7 to 9 month window for regulatory startup to be conservative.<\/p>\n\n\n\n<p>The diagram below shows Vietnam&#8217;s current clinical trial approval pathway. Since 2023, DAV technical review and Ethics Committee review run at the same time, cutting weeks off the previous sequential process. Both approvals must be received before any site can begin patient enrolment.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"550\" height=\"867\" src=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/image-1.jpeg\" alt=\"\" class=\"wp-image-11962\" style=\"width:352px;height:auto\" srcset=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/image-1.jpeg 550w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/image-1-190x300.jpeg 190w\" sizes=\"(max-width: 550px) 100vw, 550px\" \/><\/figure><\/div>\n\n\n<p class=\"has-small-font-size\"><em>Figure 1: Vietnam Phase II clinical trial approval pathway as of 2026. DAV: Drug Administration of Vietnam; EC: Ethics Committee. Parallel review (introduced 2023) means the sponsor submits to both bodies simultaneously. If either body raises queries, the sponsor responds and the review continues. Both approvals must be in hand before site initiation.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-7be278c36c5c8b664cf2c2190b2f2711\"><strong>What has changed since 2022<\/strong> in Vietnam clinical trials<\/h2>\n\n\n\n<p>Three changes matter most for sponsors reassessing Vietnam after a gap.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Ethics committee consolidation<\/h3>\n\n\n\n<p>Prior to 2022, Vietnam had multiple fragmented institutional ethics committees with inconsistent timelines and documentation standards. The Ministry of Health has since designated a smaller set of recognised independent ethics committees with standardised operating procedures. Sponsors now have clearer options for EC selection and more predictable review timelines.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">DAV capacity and staffing<\/h3>\n\n\n\n<p>DAV invested in reviewer capacity between 2022 and 2024. Technical review queues that previously extended to 12 months now typically resolve within 4 to 5 months for Phase II oncology and infectious disease submissions. Complex first-in-human or adaptive design submissions still take longer, but the improvement for standard Phase II protocols is real.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">ICH E6(R3) incorporation<\/h3>\n\n\n\n<p>Vietnam&#8217;s 2024 regulatory guidance update incorporated risk-based monitoring principles and quality management system requirements aligned with ICH E6(R3). Sponsors using risk-based monitoring plans no longer need to adapt their monitoring SOPs significantly for Vietnam submissions.<\/p>\n\n\n\n<p>What has not changed: the language barrier at many sites remains a practical challenge. Trial documentation and investigator agreements require Vietnamese translation, and CRAs who are not fluent in Vietnamese are limited in their effectiveness at monitoring visits. This is the strongest argument for using an on-ground FSP provider with native-language staff rather than deploying CRAs remotely.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-2a7f31a2fd65634d362e207a8c534bf2\">Where Vietnam&#8217;s investigator strength sits<\/h2>\n\n\n\n<p>Vietnam&#8217;s investigator landscape is concentrated at a relatively small number of high-volume tertiary centres, mostly in Hanoi and Ho Chi Minh City. The quality at these sites is competitive with Thailand and Malaysia. Outside those centres, experience and GCP compliance consistency drop off sharply.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic area<\/th><th>Investigator depth<\/th><th>Key sites<\/th><th>Notes&nbsp;<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncology<\/strong><\/td><td>Strong<\/td><td>National Cancer Hospital (K Hospital, Hanoi); Ho Chi Minh City Oncology Hospital<\/td><td>Lung, gastric, colorectal, and liver cancer are highest volume. Treatment-naive populations available in several solid tumor indications.<\/td><\/tr><tr><td><strong>Infectious disease<\/strong><\/td><td>Strong<\/td><td>National Hospital for Tropical Diseases (Hanoi); Cho Ray Hospital (Ho Chi Minh City)<\/td><td>TB, dengue, hepatitis B and C, HIV. Established research units with GCP-trained investigators.<\/td><\/tr><tr><td><strong>Cardiology and metabolic disease<\/strong><\/td><td>Moderate<\/td><td>Bach Mai Hospital (Hanoi)<\/td><td>Patient population is there. Investigator trial experience is more uneven than oncology and infectious disease.<\/td><\/tr><tr><td><strong>Neurology and CNS<\/strong><\/td><td>Limited<\/td><td>Limited<\/td><td>Investigator depth has not kept pace with oncology and infectious disease. Assess site-level feasibility carefully before committing.<\/td><\/tr><tr><td><strong>Rare disease<\/strong><\/td><td>Limited<\/td><td>Limited<\/td><td>Better suited as a supplementary country in a multi-country rare disease programme than as a standalone anchor.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-890caabc256df573ed086394e16469b0\">Site landscape: what to expect<\/h2>\n\n\n\n<p>Major research sites in Hanoi include Bach Mai Hospital, K Hospital, the National Hospital for Tropical Diseases, and Hanoi Medical University Hospital. These academic centres have dedicated clinical research units, established eTMF processes, and experience running multinational trials with US and European sponsors.<\/p>\n\n\n\n<p>Major research sites in Ho Chi Minh City include Cho Ray Hospital, University Medical Center, Ho Chi Minh City Oncology Hospital, and Children&#8217;s Hospital No. 1 for paediatric indications. Site infrastructure at these centres is comparable to the Hanoi tier.<\/p>\n\n\n\n<p>Outside the two major cities, Can Tho, Da Nang, and Hue have regional teaching hospitals with growing research capability. These centres are particularly useful for oncology and infectious disease studies requiring higher patient volumes. Site initiation timelines are longer at these sites, and monitoring logistics are more demanding.<\/p>\n\n\n\n<p>For a standard Phase II in oncology or infectious disease, two to four sites across Hanoi and Ho Chi Minh City provide sufficient patient access without overextending logistics. Adding regional sites makes sense only when central sites are genuinely insufficient for target enrolment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-5e98260d76fe32576b7aa08bbc794ab2\">Patient population and recruitment realities<\/h2>\n\n\n\n<p>Vietnam&#8217;s population of approximately 98 million is the primary recruitment advantage over Singapore and Malaysia. Patient availability in oncology and infectious disease is high, and disease prevalence in several oncology indications exceeds regional averages.<\/p>\n\n\n\n<p>Vietnam still offers meaningful treatment-naive patient access in solid tumor oncology. Competing trial density remains lower than in high-volume oncology centres in Thailand, South Korea, or India, where multiple studies often recruit from the same sites. This creates a recruitment efficiency advantage because fewer sponsors compete for the same patient population at each site.<\/p>\n\n\n\n<p>In oncology Phase II studies at Hanoi and Ho Chi Minh City sites, typical enrolment rates of 2 to 4 patients per site per month are achievable in common solid tumor indications. Rare disease and niche indications will be slower, as they are everywhere in Southeast Asia.<\/p>\n\n\n\n<p>Informed consent documentation must be in Vietnamese and reviewed by the EC. Translation costs and timelines should be built into study startup planning. For paediatric studies, Vietnam has specific guardian consent requirements that differ from adult consent procedures and require separate EC sign-off.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-32b43c8b6c3c262ba58f302e4e22d5ed\">IMP logistics and import requirements<\/h2>\n\n\n\n<p>IMP import into Vietnam is regulated by the DAV and requires an import authorisation (import licence) obtained before each shipment. This is a per-shipment requirement, not a one-time clearance. The authorisation process typically takes 4 to 8 weeks. For studies with multiple shipment cycles, import planning must begin several weeks before each anticipated shipment date.<\/p>\n\n\n\n<p>Cold-chain management is available at international airports in Hanoi (Noi Bai) and Ho Chi Minh City (Tan Son Nhat), with established handling facilities. The in-country cold-chain network beyond those airports is less developed than in Thailand or Singapore. Sponsors should verify site storage capacity and backup power availability at each clinical site, particularly for biologics requiring controlled-temperature storage.<\/p>\n\n\n\n<p>The most practical approach is to appoint an Importer of Record (IOR) with existing DAV relationships and experience navigating the import authorisation process. An IOR takes on legal importer responsibility and manages DAV clearance, customs, and in-country logistics. For more on IOR and EOR services in APAC, see Credevo&#8217;s guide to <a href=\"https:\/\/credevo.com\/articles\/2023\/09\/05\/importing-ancillaries-imps-for-clinical-trials-in-the-asia-pacific-region\/\">importing ancillaries and IMPs across the Asia-Pacific region<\/a>.<\/p>\n\n\n\n<p>The diagram below shows each step an investigational product goes through to reach a Vietnamese trial site. Every shipment requires a fresh DAV import authorisation, so planning must begin 6 to 8 weeks before each anticipated delivery.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"276\" height=\"806\" src=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/image.jpeg\" alt=\"\" class=\"wp-image-11961\" style=\"width:185px;height:auto\" srcset=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/image.jpeg 276w, https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/image-103x300.jpeg 103w\" sizes=\"(max-width: 276px) 100vw, 276px\" \/><\/figure><\/div>\n\n\n<p class=\"has-small-font-size\"><em>Figure 2: Vietnam IMP import process, step by step. IOR: Importer of Record (the locally registered entity that takes legal responsibility for importing the IMP); DAV: Drug Administration of Vietnam; IMP: Investigational Medicinal Product (the study drug or device). Noi Bai serves Hanoi; Tan Son Nhat serves Ho Chi Minh City.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-530cce3c12682391f9811f9fd839e3ad\">Vietnam vs. Thailand and Malaysia: where each wins<\/h2>\n\n\n\n<p>Sponsors evaluating Southeast Asia typically compare Vietnam against Thailand and Malaysia.<\/p>\n\n\n\n<p>Vietnam wins on patient access in oncology and infectious disease, treatment-naive populations, lower competing-trial density, and lower cost per patient. For sponsors who are primarily limited by patient acquisition rather than site quality, Vietnam is increasingly competitive.<\/p>\n\n\n\n<p>Vietnam is slower on regulatory timelines compared to Thailand\u2019s TFDA and Malaysia\u2019s NPRA for most indications. It also faces limitations in site infrastructure outside major cities, IMP logistics complexity, and investigator experience in niche or early-phase indications.<\/p>\n\n\n\n<p>The optimal regional strategy for many Phase II and III programmes is not a single-country choice. Vietnam combined with Thailand or Malaysia allows sponsors to leverage Vietnam&#8217;s patient volume and cost efficiency alongside a faster-regulating anchor country that can activate first while Vietnam is still in regulatory review. For context on APAC trial strategy broadly, see <a href=\"https:\/\/credevo.com\/articles\/2023\/08\/25\/choosing-asia-pacific-for-your-clinical-trials-strategic-insights\/\">Choosing Asia-Pacific For Your Clinical Trials: Strategic Insights<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-8d8269dd2baab75cb10064a9f154a7a0\"><strong>Conclusion<\/strong><\/h2>\n\n\n\n<p>Vietnam in 2026 is a materially different clinical trial destination from Vietnam in 2022. Shorter regulatory timelines, predictable ethics processes, and growing investigator expertise in oncology and infectious diseases make it a strong first-tier option for suitable protocols. However, logistics complexity, limited depth outside major cities, and language requirements remain challenges but can be managed with the right on-ground partner. Sponsors who dismissed Vietnam on three-year-old intelligence should reassess before locking in a Southeast Asia country plan.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-7a6959cf05c3ba03ca2106206cba262c\">Are You Evaluating Vietnam for Your Next Southeast Asia Trial?<\/h2>\n\n\n\n<p>If you want a current feasibility assessment across Hanoi and Ho Chi Minh City sites, including realistic regulatory timelines, site selection recommendations, and IMP logistics planning for your specific protocol, Credevo can run that before you commit to a country. Talk to the team by providing the details in the form below.<\/p>\n\n\n<div class=\"wpforms-container wpforms-container-full\" id=\"wpforms-11965\"><form id=\"wpforms-form-11965\" class=\"wpforms-validate wpforms-form\" data-formid=\"11965\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/articles\/wp-json\/wp\/v2\/posts\/11960\" data-token=\"52fc0f6b34a2a87f8cdf64404cbdf576\" data-token-time=\"1785333736\"><noscript class=\"wpforms-error-noscript\">Please enable JavaScript in your browser to complete this form.<\/noscript><div class=\"wpforms-field-container\"><div id=\"wpforms-11965-field_9-container\" class=\"wpforms-field wpforms-field-textarea\" data-field-id=\"9\"><label class=\"wpforms-field-label\" for=\"wpforms-11965-field_9\">Provide your requirement details here <span class=\"wpforms-required-label\">*<\/span><\/label><textarea id=\"wpforms-11965-field_9\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][9]\" required><\/textarea><\/div><div id=\"wpforms-11965-field_1-container\" class=\"wpforms-field wpforms-field-email\" data-field-id=\"1\"><label class=\"wpforms-field-label\" for=\"wpforms-11965-field_1\">What is your work email? <span class=\"wpforms-required-label\">*<\/span><\/label><input type=\"email\" id=\"wpforms-11965-field_1\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][1]\" spellcheck=\"false\" required><div class=\"wpforms-field-description\">Provide your work email, where we can contact you.<\/div><\/div><\/div><!-- .wpforms-field-container --><div class=\"wpforms-field wpforms-field-hp\"><label for=\"wpforms-11965-field-hp\" class=\"wpforms-field-label\">Message<\/label><input type=\"text\" name=\"wpforms[hp]\" id=\"wpforms-11965-field-hp\" class=\"wpforms-field-medium\"><\/div><div class=\"wpforms-recaptcha-container wpforms-is-recaptcha wpforms-is-recaptcha-type-v2\" ><div class=\"g-recaptcha\" data-sitekey=\"6LeaQRYTAAAAAPo7U8jnZJBUndxcS3f0E3Vijb2k\"><\/div><input type=\"text\" name=\"g-recaptcha-hidden\" class=\"wpforms-recaptcha-hidden\" style=\"position:absolute!important;clip:rect(0,0,0,0)!important;height:1px!important;width:1px!important;border:0!important;overflow:hidden!important;padding:0!important;margin:0!important;\" data-rule-recaptcha=\"1\"><\/div><div class=\"wpforms-submit-container\" ><input type=\"hidden\" name=\"wpforms[id]\" value=\"11965\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/11960\"><input type=\"hidden\" name=\"url_referer\" value=\"\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-11965\" class=\"wpforms-submit\" data-alt-text=\"Sending...\" data-submit-text=\"Submit\" aria-live=\"assertive\" value=\"wpforms-submit\">Submit<\/button><\/div><\/form><\/div>  <!-- .wpforms-container -->\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Frequently asked questions<\/h2>\n\n\n\n<p class=\"has-small-font-size\"><strong>Q: How long does DAV approval take for a Phase II oncology trial in Vietnam in 2026?<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">For a standard Phase II oncology protocol with a complete submission package, DAV technical review currently takes 3 to 5 months. Running ethics committee review in parallel reduces the total startup timeline to 4 to 6 months in uncomplicated cases. Complex protocols, adaptive designs, or submissions with incomplete documentation extend this. Building in 7 to 9 months from submission to first patient enrolled is a realistic conservative plan.<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Q: Does Vietnam accept FDA or EMA clinical trial data packages without reformatting?<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">Largely yes, since DAV&#8217;s ICH E6 alignment. A study protocol, Investigator&#8217;s Brochure, and safety documentation prepared to FDA or EMA standards is generally acceptable to DAV without significant reformatting. Vietnamese translations of key documents (protocol summary, patient information sheet, informed consent form) are required regardless. Some country-specific modules of the regulatory submission require Vietnamese-specific content on local site qualifications and the local EC approval.<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Q: Is Vietnam suitable for rare disease or CNS trials?<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">Not at present as a primary country. Investigator depth in rare disease and CNS indications is limited, and DAV experience reviewing these protocol types is less developed than in oncology or infectious disease. Vietnam works well as a supplementary site in a multi-country rare disease programme, adding patient access without carrying the full regulatory burden, but is not strong enough to be the anchor country for a rare disease study.<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Q: What languages are required for trial documentation in Vietnam?<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">Site-level documents, including informed consent forms, patient information sheets, and investigator agreements, must be in Vietnamese. Protocol summaries submitted to DAV and the EC require Vietnamese translation. Source documents and case report forms can be in English at most major research sites in Hanoi and Ho Chi Minh City, but this should be confirmed at feasibility stage for each site.<\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Q: Does Vietnam require a local sponsor representative or legal entity for trial conduct?<\/strong><\/p>\n\n\n\n<p class=\"has-small-font-size\">Vietnam requires a locally registered entity to act as the authorised local representative for the trial submission to DAV. This is typically a registered CRO or clinical operations company with a Vietnamese business registration. Credevo&#8217;s local entity in Vietnam fulfils this role for sponsors who do not have their own in-country presence.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Glossary<\/h2>\n\n\n\n<ul class=\"wp-block-list has-small-font-size\">\n<li><strong>APAC:<\/strong> Asia-Pacific.<\/li>\n\n\n\n<li><strong>CRA (Clinical Research Associate):<\/strong> The on-site monitor who visits investigator sites to verify data accuracy and protocol compliance.<\/li>\n\n\n\n<li><strong>CRO (Contract Research Organisation):<\/strong> A company that provides clinical trial services to sponsors on an outsourced basis.<\/li>\n\n\n\n<li><strong>CTA (Clinical Trial Authorisation):<\/strong> The regulatory approval issued by a national authority permitting a clinical trial to begin.<\/li>\n\n\n\n<li><strong>DAV (Drug Administration of Vietnam):<\/strong> Vietnam&#8217;s national regulator for medicines and clinical trials, operating under the Ministry of Health.<\/li>\n\n\n\n<li><strong>EC (Ethics Committee):<\/strong> An independent committee that reviews and approves clinical trial protocols from an ethical standpoint, separate from the regulatory authority.<\/li>\n\n\n\n<li><strong>EDC (Electronic Data Capture):<\/strong> The software system into which clinical trial data is entered at the site.<\/li>\n\n\n\n<li><strong>EOR (Employer of Record):<\/strong> A locally registered entity that employs clinical staff on behalf of a foreign sponsor, handling payroll, HR, and compliance in-country.<\/li>\n\n\n\n<li><strong>eTMF (Electronic Trial Master File):<\/strong> The system that stores all essential documents required to verify trial conduct and regulatory compliance.<\/li>\n\n\n\n<li><strong>FSP (Functional Service Provider):<\/strong> A CRO engagement model where the provider supplies staff to work within the sponsor&#8217;s own governance structure, SOPs, and systems.<\/li>\n\n\n\n<li><strong>GCP (Good Clinical Practice):<\/strong> The international quality standard for clinical trial design, conduct, and reporting. Set by the ICH.<\/li>\n\n\n\n<li><strong>HCMC:<\/strong> Ho Chi Minh City.<\/li>\n\n\n\n<li><strong>ICH (International Council for Harmonisation):<\/strong> The body that sets GCP and other pharmaceutical development standards used globally.<\/li>\n\n\n\n<li><strong>IMP (Investigational Medicinal Product):<\/strong> The study drug or device being tested in the clinical trial.<\/li>\n\n\n\n<li><strong>IOR (Importer of Record):<\/strong> A locally registered entity that takes on legal responsibility for importing the IMP into the country, managing DAV clearance, customs, and in-country logistics.<\/li>\n\n\n\n<li><strong>NPRA:<\/strong> National Pharmaceutical Regulatory Agency. Malaysia&#8217;s national drug regulator.<\/li>\n\n\n\n<li><strong>SOP (Standard Operating Procedure):<\/strong> A written instruction that defines exactly how a task must be performed.<\/li>\n\n\n\n<li><strong>TFDA:<\/strong> Thailand Food and Drug Administration. Thailand&#8217;s national regulator for medicines, food, and medical devices.<\/li>\n<\/ul>\n<\/blockquote>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vietnam has been on the periphery of APAC clinical trial planning for most of the last decade, considered after Thailand, Malaysia, and India if considered at all. That positioning is no longer accurate. Since 2022, the Drug Administration of Vietnam (DAV) has shortened approval timelines, the ethics committee landscape has become more predictable, and investigator [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":11963,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"cybocfi_hide_featured_image":"yes","footnotes":""},"categories":[12],"tags":[45,134,92],"class_list":["post-11960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trial","tag-clinicaltrials","tag-regulatory","tag-vietnam"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vietnam for Clinical Trials in 2026 | Credevo Articles<\/title>\n<meta name=\"description\" content=\"Vietnam has remained on the periphery of APAC clinical trial planning, often considered after Thailand, Malaysia, and India\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vietnam for Clinical Trials in 2026 | Credevo Articles\" \/>\n<meta property=\"og:description\" content=\"Vietnam has remained on the periphery of APAC clinical trial planning, often considered after Thailand, Malaysia, and India\" \/>\n<meta property=\"og:url\" content=\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\" \/>\n<meta property=\"og:site_name\" content=\"Credevo Articles\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/credevo\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-25T06:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-25T10:14:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Trial Expert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:site\" content=\"@gocredevo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trial Expert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\"},\"author\":{\"name\":\"Trial Expert\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec\"},\"headline\":\"Vietnam for Clinical Trials in 2026: Regulatory Landscape, Site Quality, and What Has Changed\",\"datePublished\":\"2026-07-25T06:30:00+00:00\",\"dateModified\":\"2026-07-25T10:14:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\"},\"wordCount\":2618,\"publisher\":{\"@id\":\"https:\/\/credevo.com\/articles\/#organization\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo.png\",\"keywords\":[\"clinicaltrials\",\"regulatory\",\"Vietnam\"],\"articleSection\":[\"clinical trial\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\",\"url\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\",\"name\":\"Vietnam for Clinical Trials in 2026 | Credevo Articles\",\"isPartOf\":{\"@id\":\"https:\/\/credevo.com\/articles\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo.png\",\"datePublished\":\"2026-07-25T06:30:00+00:00\",\"dateModified\":\"2026-07-25T10:14:48+00:00\",\"description\":\"Vietnam has remained on the periphery of APAC clinical trial planning, often considered after Thailand, Malaysia, and India\",\"breadcrumb\":{\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/credevo.com\/articles\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vietnam for Clinical Trials in 2026: Regulatory Landscape, Site Quality, and What Has Changed\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/credevo.com\/articles\/#website\",\"url\":\"https:\/\/credevo.com\/articles\/\",\"name\":\"Credevo\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/credevo.com\/articles\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/credevo.com\/articles\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/credevo.com\/articles\/#organization\",\"name\":\"Credevo Pte. Ltd.\",\"url\":\"https:\/\/credevo.com\/articles\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg\",\"contentUrl\":\"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg\",\"width\":320,\"height\":119,\"caption\":\"Credevo Pte. Ltd.\"},\"image\":{\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/credevo\",\"https:\/\/x.com\/gocredevo\",\"https:\/\/www.instagram.com\/credevo_official\/\",\"https:\/\/www.linkedin.com\/company\/credevo\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec\",\"name\":\"Trial Expert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/credevo.com\/articles\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g\",\"caption\":\"Trial Expert\"},\"url\":\"https:\/\/credevo.com\/articles\/author\/trialexpert\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vietnam for Clinical Trials in 2026 | Credevo Articles","description":"Vietnam has remained on the periphery of APAC clinical trial planning, often considered after Thailand, Malaysia, and India","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/","og_locale":"en_US","og_type":"article","og_title":"Vietnam for Clinical Trials in 2026 | Credevo Articles","og_description":"Vietnam has remained on the periphery of APAC clinical trial planning, often considered after Thailand, Malaysia, and India","og_url":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/","og_site_name":"Credevo Articles","article_publisher":"https:\/\/www.facebook.com\/credevo","article_published_time":"2026-07-25T06:30:00+00:00","article_modified_time":"2026-07-25T10:14:48+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo-1024x576.png","type":"image\/png"}],"author":"Trial Expert","twitter_card":"summary_large_image","twitter_creator":"@gocredevo","twitter_site":"@gocredevo","twitter_misc":{"Written by":"Trial Expert","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#article","isPartOf":{"@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/"},"author":{"name":"Trial Expert","@id":"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec"},"headline":"Vietnam for Clinical Trials in 2026: Regulatory Landscape, Site Quality, and What Has Changed","datePublished":"2026-07-25T06:30:00+00:00","dateModified":"2026-07-25T10:14:48+00:00","mainEntityOfPage":{"@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/"},"wordCount":2618,"publisher":{"@id":"https:\/\/credevo.com\/articles\/#organization"},"image":{"@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo.png","keywords":["clinicaltrials","regulatory","Vietnam"],"articleSection":["clinical trial"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/","url":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/","name":"Vietnam for Clinical Trials in 2026 | Credevo Articles","isPartOf":{"@id":"https:\/\/credevo.com\/articles\/#website"},"primaryImageOfPage":{"@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#primaryimage"},"image":{"@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#primaryimage"},"thumbnailUrl":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2026\/05\/Vietnam-for-Clinical-Trials-in-2026-Credevo.png","datePublished":"2026-07-25T06:30:00+00:00","dateModified":"2026-07-25T10:14:48+00:00","description":"Vietnam has remained on the periphery of APAC clinical trial planning, often considered after Thailand, Malaysia, and India","breadcrumb":{"@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/credevo.com\/articles\/2026\/07\/25\/vietnam-for-clinical-trials-in-2026-regulatory-landscape-site-quality-and-what-has-changed\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/credevo.com\/articles\/"},{"@type":"ListItem","position":2,"name":"Vietnam for Clinical Trials in 2026: Regulatory Landscape, Site Quality, and What Has Changed"}]},{"@type":"WebSite","@id":"https:\/\/credevo.com\/articles\/#website","url":"https:\/\/credevo.com\/articles\/","name":"Credevo","description":"","publisher":{"@id":"https:\/\/credevo.com\/articles\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/credevo.com\/articles\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/credevo.com\/articles\/#organization","name":"Credevo Pte. Ltd.","url":"https:\/\/credevo.com\/articles\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/","url":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg","contentUrl":"https:\/\/credevo.com\/articles\/wp-content\/uploads\/2021\/04\/CREDEVO-HORIZONTAL.jpg","width":320,"height":119,"caption":"Credevo Pte. Ltd."},"image":{"@id":"https:\/\/credevo.com\/articles\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/credevo","https:\/\/x.com\/gocredevo","https:\/\/www.instagram.com\/credevo_official\/","https:\/\/www.linkedin.com\/company\/credevo"]},{"@type":"Person","@id":"https:\/\/credevo.com\/articles\/#\/schema\/person\/27532d20071183286988a29ea878a2ec","name":"Trial Expert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/credevo.com\/articles\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/07b120d666645220d4fd5b49e154d849?s=96&d=mm&r=g","caption":"Trial Expert"},"url":"https:\/\/credevo.com\/articles\/author\/trialexpert\/"}]}},"_links":{"self":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/11960"}],"collection":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/comments?post=11960"}],"version-history":[{"count":2,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/11960\/revisions"}],"predecessor-version":[{"id":11968,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/posts\/11960\/revisions\/11968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/media\/11963"}],"wp:attachment":[{"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/media?parent=11960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/categories?post=11960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/credevo.com\/articles\/wp-json\/wp\/v2\/tags?post=11960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}